tac-101
Small moleculeexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2001 (NCT00077142)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-(3,5-bis(trimethylsilyl)benzamido)benzoic acid
- am555s
- am 555s
- am-555s
- tac 101
- tac-101
- tac-101
- tac-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00756782 | Phase 2 | Oct 1, 2008 | Otsuka |
| NCT00687596 | Phase 2 | Jun 1, 2008 | IQVIA, Otsuka |
| NCT00667628 | Phase 2 | Apr 1, 2008 | IQVIA, Otsuka |
| NCT00077142 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2001 | National Cancer Institute (NCI), Otsuka, University of Texas at Houston |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Otsuka | For profit | 4 | 3 | 1 | 2001 |
| IQVIA | For profit | 2 | 0 | 1 | 2008 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2001 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2001 |
4 organizations
Page 1 / 1